HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer.

Wenbai HuangYijiao ChenWenju ChangLi RenWentao TangPeng ZhengQi WuTianyu LiuYu LiuYe WeiJianmin Xu

Published in: Journal of cancer research and clinical oncology (2021)

For stage III and IV CRC patients, HER2 positivity was confirmed as an independent prognostic risk factor. It could help predict the unresponsiveness to anti-EGFR therapy for metastatic CRC.

Keyphrases

poor prognosis
small cell lung cancer
long non coding rna
epidermal growth factor receptor
end stage renal disease
tyrosine kinase
ejection fraction
newly diagnosed
risk factors
squamous cell carcinoma
prognostic factors
stem cells
patient reported outcomes